2011 IRCC International Conference Molecular Clinical Oncology May 26th-28th, 2011, Torino Italy
|
|
|
- Gladys Thompson
- 7 years ago
- Views:
Transcription
1 Updated May 23rd, IRCC International Conference Molecular Clinical Oncology May 26th-28th, 2011, Torino Italy Thursday May 26 th, 2011 (afternoon) Venue: Aula Magna Rettorato Registration Session 1. Cancer Stem Cells PierGiuseppe Pelicci (IFOM-IEO Campus, Milano- Italy) Regulation of Self Renewal in Cancer Stem Cells John Laterra (Kennedy Krieger Institute, Johns Hopkins School of Medicine, Baltimore- USA) Regulation of Glioblastoma Stem Cells: Reprogramming Factors and Receptor Tyrosine Kinases Elisa Vigna (Institute for Cancer Research, University of Torino, Candiolo- Italy) Targeted Therapy of Glioblastoma by Gene Transfer of a Monovalent Antibody against the MET Oncogene Coffee break Welcome Address by Institutional Representatives Opening Remarks Paolo Comoglio (Institute for Cancer Research, University of Torino, Candiolo- Italy) Molecular Clinical Oncology: a Novel Discipline AIRC Lecture Jeffrey A Engelman (Massachusetts General Hospital Cancer Center, Charlestown- USA) Cancer Targeted Therapy Welcome Reception
2 Friday May 27 th, 2011 (morning) Session 2. Cancer Genes Pier Paolo Pandolfi (Beth Israel Deaconess Medical Center, Boston- USA) Deconstructing the Molecular Genetics of Cancer David B Solit (Memorial Sloan Kettering Cancer Center, New York- USA) Genetic Determinants of RAS/BRAF-dependence Richard Marais (The Institute of Cancer Research, London- United Kingdom) BRAF and RAS Signalling in Melanoma: Basic Biology and Therapeutic Intervention Coffee break Ken Olaussen (Institut Gustave Roussy, Villejuif Cedex- France) Targeting DNA Repair Dysfunctionality in Lung Cancer Livio Trusolino (Institute for Cancer Research, University of Torino, Candiolo- Italy) MET in Human Cancer: Targeting Oncogene Addiction and Expedience Kristiina Iljin (Medical Biotechnology, VTT Technical Research Centre, Turku-Finland) Identification of Novel Therapeutic Strategies to Target ERG Oncogene Positive Prostate Cancer Charlotte Gueydan (Hôpital Tenon, Paris- France) A Genome-Wide Screen for Renal Cancer Genes by Targeted Transposon-Mediated Mutagenesis in Vivo Lunch
3 Friday May 27 th, 2011 (afternoon) Poster Session A: even numbers Session 3. Molecular Diagnosis and Prognosis Ian Tomlinson (Wellcome Trust Centre for Human Genetics, Oxford- UK) Predisposition to Colorectal and Other Cancers Sabine Tejpar (University Hospital Gasthuisberg, Leuven- Belgium) Molecular Subgroups in Colorectal Cancer: Prognostic and Predictive Implications Roberto Labianca (Ospedali Riuniti, Bergamo- Italy) Prognostic and Predictive Biomarkers for Colorectal Cancer in the Adjuvant Setting Coffee break Pierre Laurent-Puig (Université Paris-Descartes, Paris- France) Theranostic Biomarkers in Metastatic Colorectal Cancer Serena di Cosimo (Vall d'hebron University Hospital, VHIO, Barcelona- Spain) Introduction of Biomarkers in Early Clinical Development Social Event
4 Saturday May 28 th, 2011 (morning) Session 4. Personalized Cancer Therapies: Concepts and Targets Giorgio Scagliotti (University of Torino School of Medicine, Orbassano - Italy) Tailoring Chemotherapy in NSCLC William Sellers (Novartis Institutes for BioMedical Research, Cambridge- USA) The Genetic Basis for Cancer Therapeutics Federico Cappuzzo (Istituto Toscano Tumori, Livorno- Italy) Anti-EGFR Strategies against Metastatic NSCLC Coffee break Karen Gelmon (BC Cancer Agency, Vancouver- Canada) Hypothesis Driven Trials in Breast Cancer Alberto Bardelli (Institute for Cancer Research, University of Torino, Candiolo- Italy) Cancer Mutations and Targeted Therapies in Cells, Mice and Patients Manuela Ferracin (University of Ferrara, Italy) MicroRNA Profiling for the Identification of Cancers with Unknown Primary Tissue-of-Origin Davide Melisi (INT Fondazione Pascale, Napoli-Italy) Anti-VEGF Treatment Resistant Pancreatic Cancers Secrete not Alternative Proangiogenic but Rather Proinflammatory Factors that Induce an EMT phenotype Lunch
5 Saturday May 28 th, 2011 (afternoon) Poster Session B: odd numbers Session 5. Personalized Cancer Therapies: Overcoming Resistances William Pao (Vanderbilt University, Nashville- USA) Novel Strategies to Delay/Treat Acquired Resistance to EGFR TKIs in EGFR Mutant Lung Cancer Pasi A. Janne (Dana-Farber Cancer Institute, Boston- USA) Therapeutic Strategies for EGFR Kinase Inhibitor Resistant Cancers Fortunato Ciardiello (Second University, Napoli- Italy) Acquired Resistance to EGFR-targeted Therapies Salvatore Siena (Ospedale Niguarda Ca' Granda, Milano- Italy) Molecular Driven Selection Improves Survival of Metastatic Colorectal Cancer Patients Gianmarco Contino (Massachusetts General Hospital Cancer Center, Boston- USA) STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis Marianna Sasso (Istituto Nazionale dei Tumori, Milano-Italy Wound-healing drainages fluids promote triple negative breast cancers progression through endothelial receptors activation ECM verification test
Scientific Programme
Scientific Programme Scientific Committee Hilary Calvert UCL Cancer Institute, London, UK Luca Gianni Ospedale San Raffaele IRCCS, Milan, Italy Ana Maria Gonzalez-Angulo Cristiana Sessa Istituto Oncologico
Colorectal cancer xenopatients: A preclinical platform for precision medicine
Colorectal cancer xenopatients: A preclinical platform for precision medicine Livio Trusolino, MD PhD Laboratory of Molecular Pharmacology IRCC, Institute for Cancer Research and Treatment University of
10 th EADO Congress Vilnius, 7-10 May 2014. Ipilimumab update. Michele Maio
10 th EADO Congress Vilnius, 7-10 May 2014 Ipilimumab update Michele Maio Medical Oncology and Immunotherapy, Department of Oncology University Hospital of Siena, Istituto Toscano Tumori SIENA, ITALY Evolving
Resolving Cancer Heterogeneity:
INTERNATIONAL SYMPOSIUM ON: Resolving Cancer Heterogeneity: The way to personalised medicine Palazzo della Gran Guardia Verona (Italy), June 30 th July 2 nd, 2016 PROGRAM Organized by: ARC-Net Centre for
Understanding the Molecular and Cellular Biology of Endocrine-Related Cancers. Mont Ste. Odile, Alsace, France 11-14 September 2008
33 rd European Symposium on Hormones and Cell Regulation Understanding the Molecular and Cellular Biology of Endocrine-Related Cancers Mont Ste. Odile, Alsace, France 11-14 September 2008 Invited Speakers:
CNIO Frontiers Meetings Molecular Cancer Therapeutics Madrid, March 8 10, 2010
CNIO Frontiers Meetings Molecular Cancer Therapeutics Madrid, March 8 10, 2010 Organisers S. Gail Eckhardt, University of Colorado Denver, Aurora, USA Roy S. Herbst, The University of Texas MD Anderson
Promises and challenges of developing new drugs in oncology
3 rd International Michelangelo Conference Promises and challenges of developing new drugs in oncology Chairman: Luca Gianni, Milan I July 2-3, 2015 Venue: Museo della Scienza e della Tecnologia Via San
Breast and Lung Cancer Biomarker Research at ASCO: Changing Treatment Patterns
July 2013 Edition Vol. 7, Issue 7 Breast and Lung Cancer Biomarker Research at ASCO: Changing Treatment Patterns By Julie Katz, MPH, MPhil Biomarkers played a prominent role in the research presented in
ORGANIZERS Fundación para la Investigación Médica Aplicada FIMA Clínica Universidad de Navarra CUN
D International Symposium: Immunostimulatory monoclonal antibodies and immunomodulation: harvesting the crop Fundación Ramón Areces GENERAL INFORMATION DATES OCTOBER 18th 20th VENUE University of Navarra.
Scientific Committee Hilary Calvert UCL Cancer Institute, London, United Kingdom
Scientific Committee Hilary Calvert UCL Cancer Institute, London, United Kingdom Luca Gianni Fondazione Centro San Raffaele del Monte Tabor, Milan, Italy Ana Maria Gonzalez-Angulo M.D. Anderson Cancer
Advances in Biology and Treatment of Malignant Brain Gliomas
Advances in Biology and Treatment of Malignant Brain Gliomas International Congress 2 nd Edition Rome, June 12-13, 2014 President Giulio Maira Vice Presidents Ruggero De Maria, Antonio Iavarone, Angelo
Scientific Programme
Scientific Programme Scientific Committee Hilary Calvert UCL Cancer Institute, London, UK Luca Gianni Ospedale San Raffaele IRCCS, Milan, Italy Ana Maria Gonzalez-Angulo The University of Texas, MD Anderson
The EGFR mutation and precision therapy for lung cancer
for lung cancer Outcomes in advanced lung cancer have seen meaningful improvement in the past decade thanks to new precision drug therapies. Because tumors usually develop resistance to the drugs, scientists
Programme. Michele Grieco Dipartimento di Scienze Ambientali Seconda Università degli Studi di Napoli Naples, Italy
Programme Invited Speakers: Reuven Agami (The Netherlands), Manuela Baccarini (Austria), Allan Balmain (USA), Daniel Birnbaum (France), Anne-Lise Børresen-Dale (Norway), Carlos Caldas (UK), Silvana Canevari
Promises and challenges of developing new drugs in oncology
3 rd International Michelangelo Conference Promises and challenges of developing new drugs in oncology Chairman: Luca Gianni, Milan I July 2-3, 2015 Venue: Museo della Scienza e della Tecnologia Via San
Future Oncology: Technology, Products, Market and Service Opportunities
Brochure More information from http://www.researchandmarkets.com/reports/296370/ Future Oncology: Technology, Products, Market and Service Opportunities Description: Future Oncology is an analytical newsletter
Non Small Cell Lung Cancer: Scientific Discoveries and the Pursuit of Progress
Non Small Cell Lung Cancer: Scientific Discoveries and the Pursuit of Progress Lung Cancer Accounts for 14% of All New Cancer Diagnoses in the United States 1 Lung cancer is the second most common malignancy
Sezione di Oncologia. [Workshop] LEARNING at the LEANING tower Pisa Colorectal Cancer 2015
![Sezione di Oncologia. [Workshop] LEARNING at the LEANING tower Pisa Colorectal Cancer 2015](/thumbs/27/10571939.jpg "Sezione di Oncologia. [Workshop] LEARNING at the LEANING tower Pisa Colorectal Cancer 2015")
[Workshop] LEARNING at the LEANING tower Pisa Colorectal Cancer 2015 Pisa, 16-17 Novembre 2015 [ Programma preliminare] Lunedì, 16 novembre 13.30 Registration 13.45 Introduction and welcome Alfredo Falcone,
ADDARIO LUNG CANCER MEDICAL INSTITUTE
ADDARIO LUNG CANCER MEDICAL INSTITUTE Dedicated to catalyzing and accelerating the discovery, development and delivery of new and more effective treatment options for lung cancer patients. Contact: Steven
Sommaire projets sélectionnés mesure 29: Soutien à la recherche translationnelle
Sommaire projets sélectionnés mesure 29: Soutien à la recherche translationnelle TITLE PROJET NOM HOPITAL Assessment of tumor angiogenesis using PET/CT with 18 F-Galacto- RGD. (PNC_29_001) Division of
Targeted Therapy What the Surgeon Needs to Know
Targeted Therapy What the Surgeon Needs to Know AATS Focus in Thoracic Surgery 2014 David R. Jones, M.D. Professor & Chief, Thoracic Surgery Memorial Sloan Kettering Cancer Center I have no disclosures
FARMACI PERSONALIZZATI PER
ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI FONDAZIONE G. Pascale NAPOLI SC Biologia Cellulare e Bioterapie CENTRO RICERCHE ONCOLOGICHE MERCOGLIANO (AV) Laboratorio di Farmacogenomica FARMACI
58th ANNUAL MEETING OF THE ITALIAN CANCER SOCIETY REVOLUTIONARY ROAD. VERONA SEPTEMBER 5-8 2016 Palazzo della GRAN GUARDIA. First Announcement
SEPTEMBER 5-8 2016 Palazzo della GRAN GUARDIA ABSTRACT DEADLINE May 2, 2016 First Announcement Scientific Coordinators Davide Melisi (Verona) Giampaolo Tortora (Verona) Local Scientific Committee Vincenzo
How To Learn More About Melanoma
PROGRAMMA SCIENTIFICO MELANOMA BRIDGE 2012, DECEMBER 2 ND -4 TH 2012 Presidents: Paolo A. Ascierto, Francesco M. Marincola and Nicola Mozzillo Scientific Board Paolo A. Ascierto Gennaro Ciliberto Bernard
NAPLES - DECEMBER 5-6, 2011 Hotel San Francesco al Monte
Melanoma Research: A Bridge from Naples to the World th th NAPLES - DECEMBER 5-6, 2011 Hotel San Francesco al Monte Corso Vittorio Emanuele, 328 www.bridgenaples.com (SOCIETY FOR IMMUNOTHERAPY OF CANCER
David Altshuler, M.D., Ph.D. Deputy Director and Chief Academic Officer, Broad Institute of Harvard and MIT Cambridge, Massachusetts, U.S.
David Altshuler, M.D., Ph.D. Deputy Director and Chief Academic Officer, Broad Institute of Harvard and MIT Cambridge, Massachusetts, U.S. Endocrinologist and human geneticist David Altshuler is a professor
REACHING OUT THROUGH THE WEB MILAN BREAST CANCER CONFERENCE Webcast and residential. 23/26 june 2015
REACHING OUT THROUGH THE WEB MILAN BREAST CANCER CONFERENCE Webcast and residential 23/26 june 2015 Tuesday 23 rd June 7.30 Registration 7.45 Opening session: W. Audretsch (Breast Center, Dusseldorf),
1 page Overview. CONCURRENT 1D, 1E, 1F Biology & Pathogenesis Multi-Modality Immunology 1
1 page Overview 21 Oct Tuesday 1500 on REGISTRATION 1800 Welcome Reception & Cocktails at the Cape Town International Conference Centre (CTICC) 22 Oct Wednesday 0730 REGISTRATION 0830 OPENING 0900 PLENARY
What is New in Oncology. Michael J Messino, MD Cancer Care of WNC An affiliate of Mission hospitals
What is New in Oncology Michael J Messino, MD Cancer Care of WNC An affiliate of Mission hospitals Personalized Medicine Personalized Genomics Genomic Medicine Precision Medicine Definition Application
Wednesday, January 24, 2007
Wednesday, January 24, 2007 h. 11.00/12.30 Registration and poster positioning (just for Poster Session I) h. 13.00/14.30 Welcome lunch h. 14.30/14.40 Opening remarks Enrico Garattini, Istituto Ricerche
The following information is only meant for people who have been diagnosed with advanced non-small cell
Important information for people with advanced non-small cell lung cancer The following information is only meant for people who have been diagnosed with advanced non-small cell lung cancer (NSCLC). NSCLC
ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials)
ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials) 3 Integrated Trials Testing Targeted Therapy in Early Stage Lung Cancer Part of NCI s Precision Medicine Effort in
Pharmacogenomic markers in EGFR-targeted therapy of lung cancer
Pharmacogenomic markers in EGFR-targeted therapy of lung cancer Rafal Dziadziuszko, MD, PhD University of Colorado Cancer Center, Aurora, CO, USA Medical University of Gdansk, Poland EMEA Workshop on Biomarkers,
Prognostic and Predictive Factors in Oncology. Mustafa Benekli, M.D.
Prognostic and Predictive Factors in Oncology Mustafa Benekli, M.D. NCI Definitions ESMO Course -Essentials of Medical Oncology -Istanbul 2 Prognostic factor: NCI Definition A situation or condition, or
Nuevas tecnologías basadas en biomarcadores para oncología
Nuevas tecnologías basadas en biomarcadores para oncología Simposio ASEBIO 14 de marzo 2013, PCB Jose Jimeno, MD, PhD Co-Founder / Vice Chairman Pangaea Biotech SL Barcelona, Spain PANGAEA BIOTECH BUSINESS
Stem cells: the diverging goals of regenerative medicine and oncology ROME JULY 1-2, 2010 CALL FOR ABSTRACTS
Preliminary Programme INTERNATIONAL CONFERENCE Promoted by: Consiglio Nazionale delle Ricerche In collaboration with Stem cells: the diverging goals of regenerative medicine and oncology CHAIRMEN: KENNETH
Public-Private Partnerships in early phase clinical research: Spurring access to innovative therapeutics
EPAAC WP8 Research Forum - 2 July, Sofitel Hotel Europe, Brussels Public-Private Partnerships in early phase clinical research: Spurring access to innovative therapeutics JY Blay, Past President EORTC
Future Directions in Clinical Research. Karen Kelly, MD Associate Director for Clinical Research UC Davis Cancer Center
Future Directions in Clinical Research Karen Kelly, MD Associate Director for Clinical Research UC Davis Cancer Center Outline 1. Status of Cancer Treatment 2. Overview of Clinical Research at UCDCC 3.
REFERENCE CODE GDHC212DFR PUBLICAT ION DATE JUNE 2013 GSK1572932A (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC212DFR PUBLICAT ION DATE JUNE 2013 GSK1572932A (NON-SMALL CELL LUNG CANCER) GSK1572932A (NON-SMALL CELL LUNG CANCER) - Executive Summary GSK1572932A (MAGE-A3): Key Metrics in NSCLC Markets
Genomic Medicine The Future of Cancer Care. Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America
Genomic Medicine The Future of Cancer Care Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America Personalized Medicine Personalized health care is a broad term for interventions
Scientific Committee. Andrés Cervantes (ESMO, GEICO) Antonio González (ESMO, GEICO) Andrés Poveda (ESMO, GEICO) Jan B. Vermorken (ESMO, GEICO)
Under the Auspices of Organized by 10th International Symposium Advanced Ovarian Cancer: Optimal Therapy. Update Valencia, Spain, 6th March 2015 Directors Andrés Poveda Fundación Instituto Valenciano de
FAMILIAL CANCER ESO, CNIO AND NRCO CONFERENCE ON. 19-20 May 2016 Madrid, Spain. Chairs: R. Eeles, UK W.D. Foulkes, CA M. Robledo, ES H.
INSIDE TRACK CONFERENCE ESO, CNIO AND NRCO CONFERENCE ON FAMILIAL CANCER 19-20 May 2016 Madrid, Spain Chairs: R. Eeles, UK W.D. Foulkes, CA M. Robledo, ES H. Vasen, NL FOREWORD The ESO, CNIO and NRCO Conference
Médecine de précision médecine personnalisée en Oncologie. Fabien Calvo, Directeur Recherche et Innovation, INCa, Directeur ITMO Cancer, AVIESAN
Médecine de précision médecine personnalisée en Oncologie Fabien Calvo, Directeur Recherche et Innovation, INCa, Directeur ITMO Cancer, AVIESAN Successful targeted drug development Rapid identification
CANCER SUMMER SCHOOL 2014 PROGRAM
CANCER SUMMER SCHOOL 2014 PROGRAM Monday 30 th June 0 Participant Arrival & Coffee Break ED 3 room Presentation of the program Presentation of the participants and of their research interests/experiences
ESO INSIDE TRACK CONFERENCE. 4 th FAMILIAL CANCER CONFERENCE. 7-8 June 2010 Madrid, Spain. Chair: J. Benítez, ES - H. Vasen, NL MADRID 07/06/10
ESO INSIDE TRACK CONFERENCE MADRID 07/06/10 4 th FAMILIAL CANCER CONFERENCE 7-8 June 2010 Madrid, Spain Chair: J. Benítez, ES - H. Vasen, NL APPLICATION AND ABSTRACT SUBMISSION Poster abstract deadline
AICC Italian Association of Cell Culture
AICC Italian Association of Cell Culture The AICC was founded in Bologna in 1980 as an Italian wing of the "European Tissue Culture Society" (ETCS) in order to promote the study and application of in vitro
Avastin (Renal Cell Carcinoma) - Analysis and Forecasts to 2022
Brochure More information from http://www.researchandmarkets.com/reports/2228475/ Avastin (Renal Cell Carcinoma) - Analysis and Forecasts to 2022 Description: Avastin (Renal Cell Carcinoma) Analysis and
Targeted Therapies in Lung Cancer
Targeted Therapies in Lung Cancer I Edited by: Simona Carnio Thoracic Oncology Division - St Luigi Hospital Orbassano (TO) - Italy Silvia Novello Department of Oncology - University of Torino - Italy Why
targeted therapy a guide for the patient
targeted therapy FOR LUNG CANCER a guide for the patient TABLE OF CONTENTS lung cancer basics... 2-3 Gene changes... 4-5 Testing... 7-8 Targeted therapy... 9-11 Drugs Targeting EGFR... 12 Drugs Targeting
CONTRASTS IN PHARMACOLOGY 2.0
CONTRASTS IN PHARMACOLOGY 2.0 Turin (Italy), May 14-16, 2015 Organized by DIPARTIMENTO DI SCIENZE DEL FARMACO UNIVERSITY OF PIEMONTE ORIENTALE Promoted by PRELIMINARY PROGRAM (Via Nino Costa, 8) Under
Resumen Curricular de los Profesores. Jesse Boehm
Resumen Curricular de los Profesores Jesse Boehm Jesse Boehm is the assistant director of the Cancer Program at the Broad Institute. In this role, he works closely with Cancer Program director Todd Golub
Transgene Presents Additional Positive Clinical Data from Phase 2b Part of TIME Trial with TG4010 at ESMO
Transgene Presents Additional Positive Clinical Data from Phase 2b Part of TIME Trial with TG4010 at ESMO Statistically significant difference in progression-free survival continues to be seen in non-squamous
ALK+ lung cancer and the Blood-Brain Barrier (BBB) A concise guide
ALK+ lung cancer and the Blood-Brain Barrier (BBB) A concise guide Contents Section Page number Section 1: Lung cancer and ALK+ NSCLC 3 Section 2: The Blood-Brain Barrier (BBB): What and why? 4 Section
GENETIC PROFILES AND TARGETED TREATMENT OF CANCER - PERSONALIZED MEDICINE
GENETIC PROFILES AND TARGETED TREATMENT OF CANCER - PERSONALIZED MEDICINE Branko Zakotnik MD, PhD Department of Medical Oncology Institute of Oncology Ljubljana 1 I have no conflict of interest to declare
30-31. Advancesincancer immunologyand immunotherapy. announcement. October2015. Royal Olympic Hotel Athens
Advancesincancer immunologyand immunotherapy 30-31 October2015 Royal Olympic Hotel Athens announcement Organizer Hellenic Oncology Research Group (HORG) Symposium chairs N. Kentepozidis, A. Kotsakis, M.
Conference Program. Molecular classification of breast tumors based on multiplatform analysis Charles M. Perou
Conference Program Saturday, October 17 7:00 p.m.-8:30 p.m. Welcome and Keynote Lectures Session Chairperson: Jane E. Visvader, Walter and Eliza Hall Institute of Medical Research, Parkville, Australia
Pharmacogenomic Approaches. Luis Paz-Ares Hospital Universitario Virgen del Rocio Seville, Spain
Pharmacogenomic Approaches Luis Paz-Ares Hospital Universitario Virgen del Rocio Seville, Spain Pharmacogenetics & Pharmacogenomics Medicine tailored to the individual Genetic information, including the
Worldwide Collaborations in Molecular Profiling
Worldwide Collaborations in Molecular Profiling Lillian L. Siu, MD Director, Phase I Program and Cancer Genomics Program Princess Margaret Cancer Centre Lillian Siu, MD Contracted Research: Novartis, Pfizer,
Proposal for Tyrosine Kinase Inhibitors for Non Small Cell Lung Cancer
31 May 2012 Proposal for Tyrosine Kinase Inhibitors for Non Small Cell Lung Cancer PHARMAC is seeking feedback on a proposal to: fund gefitinib (Iressa) as a first line treatment for patients with locally
Cancer Treatments Subcommittee of PTAC Meeting held 2 March 2012. (minutes for web publishing)
Cancer Treatments Subcommittee of PTAC Meeting held 2 March 2012 (minutes for web publishing) Cancer Treatments Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology
Therapeutic Goods Administration Orphan Drugs Program: Discussion paper
Therapeutic Goods Administration Orphan Drugs Program: Discussion paper Submission from the Clinical Oncology Society of Australia and Cancer Council Australia March 2015 The Clinical Oncology Society
EACR AACR SIC. from Cancer Biology to the Clinic. Advance Programme & Call for Abstracts ITALY 20-23 JUNE. Anticancer Drug Action and Drug Resistance:
Anticancer Drug Action and Drug Resistance: from Cancer Biology to the Clinic Organised by: Advance Programme & Call for Abstracts -- ORGANIZING COMMITTEE n Richard Marais (UK) - Conference Co-Chair n
Biomarker Trends in Breast Cancer Research
WHITE PAPER Biomarker Trends in Breast Cancer Research Jason Hill, PhD, Associate Director, External Science Affairs, Quintiles Quintiles examines the novel drug combinations and mechanisms of action that
Corporate Medical Policy
Corporate Medical Policy Molecular Analysis for Targeted Therapy for Non-Small Cell Lung File Name: Origination: Last CAP Review: Next CAP Review: Last Review: molecular_analysis_for_targeted_therapy_for_non_small_cell_lung_cancer
Curriculum Vitae - Sara Gandini
Curriculum Vitae - Sara Gandini Academic information 2004 PHD IN CANCER STUDIES at the University of Birmingham (Public Health), UK. Thesis: Meta-Analysis in Cancer Epidemiology. 1995 MASTER OF SCIENCE
SPEAKERS AND CHAIRMEN
44 th COURSE ON ADVANCES IN NEPHROLOGY, DIALYSIS AND TRANSPLANTATION Milan, December 6-9, 2012 Centro Congressi Milan Marriott Hotel Via Washington, 66 - Milan Directors of the Course G. D'AMICO - P. MESSA
Individualizing Your Lung Cancer Care: Informing Decisions Through Biomarker Testing
Individualizing Your Lung Cancer Care: Informing Decisions Through Biomarker Testing These Are Hopeful Times for Lung Cancer Survivors When people first learn they have cancer, they are often afraid. But
STRESA 31/03/11 RARE SOLID CANCERS: AN INTRODUCTION. 31 March - 1 April 2011 Stresa, Italy. Chairs: P.G. Casali, IT - G. Gatta, IT
ESO ADVANCED COURSES, SEMINARS AND SYMPOSIA 31/03/11 RARE SOLID CANCERS: AN INTRODUCTION 31 March - 1 April 2011 Stresa, Italy Chairs: P.G. Casali, IT - G. Gatta, IT STRESA In collaboration with COURSE
Understanding series. new. directions. 1-800-298-2436 LungCancerAlliance.org. A guide for the patient
Understanding series LUNG CANCER: new treatment directions 1-800-298-2436 LungCancerAlliance.org A guide for the patient TABLE OF CONTENTS What s New in lung cancer? Advancements...4 Changes in genes that
CANCER RESEARCH UK STRATIFIED MEDICINE PROGRAMME IAN WALKER PHD, MBA HEAD OF STRATIFIED MEDICINE
CANCER RESEARCH UK STRATIFIED MEDICINE PROGRAMME IAN WALKER PHD, MBA HEAD OF STRATIFIED MEDICINE Agenda Introduction to Cancer Research UK CRUK Stratified Medicine Programme Key Challenges and Lessons
ESO INSIDE TRACK CONFERENCE. 4 th FAMILIAL CANCER CONFERENCE. 7-8 June 2010 Madrid, Spain. Chair: J. Benítez, ES - H. Vasen, NL MADRID 07/06/10
ESO INSIDE TRACK CONFERENCE MADRID 07/06/10 4 th FAMILIAL CANCER CONFERENCE 7-8 June 2010 Madrid, Spain Chair: J. Benítez, ES - H. Vasen, NL APPLICATION AND ABSTRACT SUBMISSION Poster abstract deadline
E UROPEAN PERSONAL INFORMATION
E UROPEAN CURRICULUM VITAE FORMAT PERSONAL INFORMATION Name Work Address ARTURO CHITI Humanitas University, Via A. Manzoni 113, 20089 Rozzano (MI), Italy Nuclear Medicine Department, Humanitas Research
MOLOGEN AG German Equity Forum 2015
German Equity Forum 2015 Dr. Mariola Söhngen Chief Executive Officer Frankfurt am Main 24 November 2015 We are Pioneers in the Field of Immunotherapies Biotechnology company with focus on immunotherapies
ELCC 2015 Industry Satellite Symposium The Treatment Roadmap for Squamous NSCLC. Thursday 16th April 2015 13:10 14:20 Room C
ELCC 2015 Industry Satellite Symposium The Treatment Roadmap for Squamous NSCLC Thursday 16th April 2015 13:10 14:20 Room C 1 Contents Programme.... 2 Welcome message.... 3 Faculty biographies.... 4 Symposium
Guideline Development The American Society of Clinical Oncology
Assessing Genomic Sequencing Information for Health Care Decision Making Decision Making Once Evidence is Assessed/Graded Evaluated Guideline Development The American Society of Clinical Oncology Gary
Lung cancer is not just one disease. There are two main types of lung cancer:
1. What is lung cancer? 2. How common is lung cancer? 3. What are the risk factors for lung cancer? 4. What are the signs and symptoms of lung cancer? 5. How is lung cancer diagnosed? 6. What are the available
Clinical Cancer Research: Alternative IRB Models and Enhancing Progress
Clinical Cancer Research: Alternative IRB Models and Enhancing Progress Lowell E. Schnipper, M.D. Berenson Professor of Medicine Chief, Hematology-Oncology Beth Israel Deaconess Medical Dynamics of Clinical
Harmesh Naik, MD. Hope Cancer Clinic HOW DO I MANAGE STAGE 4 NSCLC IN 2012: STATE OF THE ART
Harmesh Naik, MD. Hope Cancer Clinic HOW DO I MANAGE STAGE 4 NSCLC IN 2012: STATE OF THE ART Goals Discuss treatment options for stage 4 lung cancer: New and old Discuss new developments in personalized
New Treatment Advances for Breast Cancer
New Treatment Advances for Breast Cancer Guest Expert: Lyndsay, MD Director of the Yale Cancer Center Breast Cancer Program Gina ng, MD www.wnpr.org www.yalecancercenter.org Welcome to Yale Cancer Center
Developments in Biomarker Identification and Validation for Lung Cancer
Developments in Biomarker Identification and Validation for Lung Cancer Alexandre Passioukov, MD, PhD Alexandre.Passioukov@eortc.be Contents Introduction Lung cancer pathogenesis NSCLC treatment options
Immune Therapy for Pancreatic Cancer
Immune Therapy for Pancreatic Cancer December 16, 2014 If you experience technical difficulty during the presentation: Contact WebEx Technical Support directly at: US Toll Free: 1-866-229-3239 Toll Only:
ONCOLOGY NURSING 7 TH ESO-EONS MASTERCLASS IN. 8-13 March 2014 Ermatingen (Lake Constance) Switzerland MASTERCLASS
MASTERCLASS Photo: Turm by Stephan Balkenhol - A Sculpture for Wolfsberg Photographer: Ralph Feiner, Architekturfotografie, Malans 7 TH ESO-EONS MASTERCLASS IN ONCOLOGY NURSING 8-13 March 2014 Ermatingen
1. Le mutazioni di KRAS hanno tutte lo stesso significato clinico?
EGFR downstream pathways KRAS domande frequenti ed importanti. Luca Mazzucchelli Istituto cantonale di patologia Locarno )'"* )-# %& # +%,!"# '( "#$ Anti-EGFR monoclonal antibodies (MoAbs) Cetuximab and
Cellular, Molecular, and Biochemical Targets in Breast Cancer
Cellular, Molecular, and Biochemical Targets in Breast Cancer Kristy Kummerow Ingrid Meszoely December 12, 2012 VUMC Resident Bonus Conference One size fits all surgical treatment of breast cancer Wilhelm
KRAS Mutation Analysis in Non-Small Cell Lung Cancer (NSCLC) Original Policy Date
MP 2.04.43 KRAS Mutation Analysis in Non-Small Cell Lung Cancer (NSCLC) Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with literature search/12:2013
Complex Systems BioMedicine: Molecules, Signals, Networks, Diseases
The International School of Advanced Molecular BioMedicine Complex Systems BioMedicine: Molecules, Signals, Networks, Diseases AciTrezza (Catania), Italy, October 2nd-6th, 2009 Hieronymus Bosch: Garden
A Letter from MabVax Therapeutics President and Chief Executive Officer
A Letter from MabVax Therapeutics President and Chief Executive Officer Dear Fellow Stockholder: You have invested in MabVax Therapeutics because you share our passion for finding new therapies for the
2 nd ESSO Advanced Course on the Surgical and Medical Management of Melanoma
2 nd ESSO Advanced Course on the Surgical and Medical Management of Melanoma Focus on stage III and IV melanoma In partnership with the Society of Surgical Oncology (SSO) 12-14 November 2015 ATHENS (GR)
Curriculum Vitae Massimo M. Santoro, PhD
Curriculum Vitae Massimo M. Santoro, PhD Current position Full Professor, KU Leuven, Belgium Group Leader, VIB-Vesalius Research Center, Leuven, Belgium Education 1994 BS in Biology summa cum laude and
TEACH Summer School Cascais, Portugal 3-7 July, 2016. Training and Education for Advanced Clinicians and HCPs in Personalised Medicine
TEACH Summer School Cascais, Portugal 3-7 July, 2016 Training and Education for Advanced Clinicians and HCPs in Personalised Medicine TEACH Summer School Cascais, Portugal 3-7 July, 2016 Objectives There
Data from an interim analysis from the pivotal Phase 3 trial of YONDELIS in soft tissue sarcoma, SAR-3007, will be presented in an oral presentation
PharmaMar announces new advances in oncology at ASCO 2015 for its compounds YONDELIS and PM1183 in small cell lung cancer, soft tissue sarcoma, and mesothelioma Compelling clinical activity of PM1183 in
The CASP8 rs3834129 polymorphism and breast cancer risk in BRCA1 mutation carriers.
The CASP8 rs3834129 polymorphism and breast cancer risk in BRCA1 mutation carriers. Irene Catucci 1,2,12, Paolo Verderio 3,12, Sara Pizzamiglio 3,12, Siranoush Manoukian 4, Bernard Peissel 4, Daniela Zaffaroni
REPORT ASCO 2002 ORLANDO : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group
REPORT ASCO 2002 ORLANDO : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group In the 2002 edition of the ASCO meeting, a total of 315 abstracts in the field of respiratory
If you were diagnosed with cancer today, what would your chances of survival be?
Q.1 If you were diagnosed with cancer today, what would your chances of survival be? Ongoing medical research from the last two decades has seen the cancer survival rate increase by more than 40%. However
ITT Advanced Medical Technologies - A Programmer's Overview
ITT Advanced Medical Technologies (Ileri Tip Teknolojileri) ITT Advanced Medical Technologies (Ileri Tip Teknolojileri) is a biotechnology company (SME) established in Turkey. Its activity area is research,
REFERENCE CODE GDHC256CFR PUBLICAT ION DATE SEPTEMBER 2014 HER2-POSITIVE BREAST CANCER CHINA DRUG FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC256CFR PUBLICAT ION DATE SEPTEMBER 2014 HER2-POSITIVE BREAST CANCER CHINA DRUG FORECAST AND MARKET ANALYSIS TO 2023 Executive Summary Sales for HER2-Positive Breast Cancer in China Market
Chromosome Conference
ANNOUNCING The Fiftieth Annual Great Lakes DATES: May 17-18, 2012 LOCATION: 89 Chestnut Street, University of Toronto ACCOMMODATION: Conference rates are not available at the Metropolitan Hotel or at the
OPEN Regional Meeting June 26 and June 27, 2015 Hyatt Regency Pier Sixty Six 2301 Southeast 17th Street Fort Lauderdale, Florida, 33316 AGENDA
OPEN Regional Meeting June 26 and June 27, 2015 Hyatt Regency Pier Sixty Six 2301 Southeast 17th Street Fort Lauderdale, Florida, 33316 Friday, June 26 AGENDA 10:00 am - 10:45 am Registration; Breakfast
Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost-Effectiveness
Department of Veterans Affairs Health Services Research & Development Service Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost-Effectiveness
Breakthrough Treatment Options for Breast Cancer
Breakthrough Treatment Options for Breast Cancer Guest Expert: Lyndsay, MD Associate Professor of Medical Oncology, Yale Cancer Center www.wnpr.org www.yalecancercenter.org Welcome to Yale Cancer Center